Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 months ago

Possible Interaction: Asymmetric Dimethylarginine and Nebivolol

Research Papers that Mention the Interaction

Although the mechanism by which nebivolol reduces circulating ADMA in hypertensive patients remains unclear, our ex vivo results suggest that the upregulation of DDAH2 expression may have a role.
RESULTS ADMA levels were significantly decreased and FMD increased only in patients receiving nebivolol (P < 0.01).
RESULTS ADMA levels were significantly decreased and FMD increased only in patients receiving nebivolol (P < 0.01).
American journal of hypertension  •  2008  |  View Paper
In conclusion, the results of this study demonstrate that nebivolol reduces ADMA concentration by increasing DDAH2 expression and activity.
Nebivolol dose-dependently decreased ADMA/symmetric dimethylarginine (SDMA) ratio (p from <0.01 to <0.001).
Pharmacological research  •  2007  |  View Paper
Further, nebivolol reduced the plasma and kidney ADMA levels by increasing DDAH2 expression and decreasing PRMT1 expression.
  •  2018  |  View Paper
Further, nebivolol reduced the plasma and kidney ADMA levels by increasing DDAH2 expression and decreasing PRMT1 expression.
Pharmacological reports : PR  •  2018  |  View Paper
Nebivolol inhibited the ADMA-induced enhancements in tone and reversed the effects of ADMA on Ach-induced relaxation.
Clinical and experimental hypertension  •  2016  |  View Paper
Nebivolol increased plasma NO and NOS activity, attenuated ADMA level.
Our results indicate that nebivolol reduces plasma ADMA level in SHR by increasing its hydrolysis and reducing its generation.
The influence of nebivolol on ADMA is complex, and the mechanism remains to be investigated.
Vascular pharmacology  •  2011  |  View Paper